The impact of rituximab on the international prognostic index in aggressive B cell lymphoma

Objective To investigate the impact of rituximab on the international prognostic index(IPI) in aggressive B cell lymphoma.Methods The data of 64 patients with aggressive B cell lymphomas who received rituximab-based treatment were analyzed retrospectively in order to find out the impact of rituximab on the IPI.Results Rituximab-based treatment could achieve a continues remission rate of 65.6% in aggressive B cell lymphoma.The stage of the disease and serum LDH levels could predict the outcomes of the disease,however,there was no significant difference in patients' prognosis among the four group divided according to IPI.Conclusion Rituximab-based treatment can get good outcome in patients with aggressive B cell lymphoma.The stage of the disease and serum LDH levels can predict the outcomes of the disease,while it need to be revised that the patients' prognosis is divided into different groups according to IPI.